Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)

NCT07681778 | Not Yet Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: OPGx-RDH12-1001
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 3

Brief Summary

This study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare genetic eye disease that leads to severe vision loss. The treatment is delivered as a one-time injection (300 µL) into the retina (subretinal space) of the worse-seeing eye, using a method similar to approved gene therapies like Luxturna. The study is designed to evaluate safety and effectiveness at two dose levels (1E11 and 3E11 viral genomes per eye) in small groups of 5 participants. Each group begins cautiously with 2 adults (age ≥18), treated at least one month apart, followed by FDA review before allowing adolescents (ages 12-17) to participate. An independent monitoring committee (IDMC) oversees safety throughout. After 3 adolescents are treated and followed for 3 months, the committee reviews all data to decide whether to move to a higher dose. However, if the lower dose (1E11 vg/eye) shows strong effectiveness in the first group, the study may expand by treating more adolescents at that same dose instead of increasing it further.

Conditions

Leber Congenital Amaurosis; Leber Congenital Amaurosis (LCA)

Keywords

Gene therapy; IRD; LCA; Leber Congenital Amaurosis; OPGx-RDH12

Outcome Measures

Primary Outcomes (4)

• Number of dose-limiting toxicity (DLT) events at the proposed doses

  5 Years

• Number and severity of procedure-related AEs

  5 Years

• Number and severity of AEs related to OPGx-RDH12

  5 Years

• Qualitative assessment of cross-sectional spectral-domain optical coherence tomography (SD-OCT), fundus photography, and fundus autofluorescence (FAF) images

  5 Years

Secondary Outcomes (11)

• Change from baseline best corrected visual acuity (BCVA) with manifest refraction

  5 Years

• Change from baseline Low luminance visual acuity (LLVA)

  5 Years

• Change from baseline Kinetic visual fields

  5 Years

• Change in baseline Microperimetry

  5 Years

• Change from baseline Light- and dark-adapted full-field sensitivity testing (FST)

  5 Years

Study Arms (1)

OPGx-RDH12

EXPERIMENTAL

Administration of OPGx-RDH12 will occur via a cannula into the subretinal space, using the standard technique for delivery of other adeno-associated virus (AAV) therapies including Luxturna®. A dose of 1E11 vg/eye will be injected sub-retinally one time into the treatment eye. The treatment eye will be the eye with the worst visual function (as determined by visual acuity, full-field sensitivity testing \[FST\] and kinetic perimetry) or the non-dominant eye in cases of bilateral symmetric disease.

Drug: OPGx-RDH12

Interventions

OPGx-RDH12 DRUG

Experimental gene therapy

OPGx-RDH12

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years (adult participants) or 12-17 years (adolescent participants) at the time of consent/assent.
• Provide written informed consent and/or assent prior to any study procedures.
• Willing to adhere to the clinical protocol and follow directions of the Investigator regarding post-surgery restrictions.
• Are a good candidate for surgery, per the Investigator's judgment.
• Have LCA with autosomal-recessive RDH12 mutation(s), confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Historic testing, up to 15 years prior to date of consent, may be considered.
• Clinical diagnosis of LCA with RDH12 mutation(s), in the judgment of the Investigator.
• BCVA 20/200 (1.0 logarithm of the minimum angle of resolution \[logMAR\]) or worse for the sentinel adult in each cohort; BCVA 20/40 (0.5 logMAR) or worse for all subsequent participants in each cohort.

You may not qualify if:

• Women of childbearing potential (WOCBP) who are pregnant, lactating, and/or unwilling to use effective contraception from Screening through 1 year after IMP administration.
• Men who are unwilling to use effective contraception from Screening through 180 days after IMP administration.
• Have an ocular infection, a pre-existing eye condition, or a complicating systemic disease that could preclude the planned surgery or any future ocular surgery. This includes individuals who are immunocompromised and/or on continuous systemic immunosuppressive therapy.
• Have a past or current condition that may preclude participation in the study, interfere with outcome measure testing or test results, or otherwise make the potential participant unsuitable for the study.
• Have previously received gene therapy of any kind.
• In either eye, have undergone intraocular surgery within 90 days prior to planned IMP administration or have active inflammation at Screening resulting from prior ocular surgery.
• Have used any investigational device or investigational drug within 90 days (or 5 half-lives of the drug, whichever is longer) prior to planned IMP administration or intend to participate in another drug or device study during the same period as the current study.
• Have received anticoagulant therapy within 2 weeks prior to planned IMP administration.
• Currently use medications that are potentially neuroprotective/beneficial or retinotoxic.
• Are incapable of performing visual function testing (e.g., FST), with or without assistance, for reason other than poor vision.
• Have any contraindication to a course of oral steroids, in the opinion of the Investigator.
• Have a known history of hypersensitivity to constituents or excipients in the pharmaceutical formulation of the IMP.
• Have a known or active infection of human immunodeficiency virus (HIV) or hepatitis B or C virus.
• Have a known or active infection of herpes simplex virus with ocular manifestations.
• Are an employee of the Sponsor or a relative of the Investigator or investigative site staff.

Sponsors & Collaborators

• Opus Genetics, Inc: lead

Study Sites (3)

Associated Retina Consultants

Phoenix, Arizona, 85020, United States

Location

Perelman School of Medicine, University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Retina Consultants of Texas & Retina Group Inc.

Houston, Texas, 77056, United States

Location

Related Links

• Opus website with description of programs

MeSH Terms

Conditions

Leber Congenital Amaurosis

Condition Hierarchy (Ancestors)

Eye Diseases, Hereditary; Eye Diseases; Retinal Diseases

Central Study Contacts

Study Director

CONTACT

984-884-6030; ct.gov_inquiries@opusgtx.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2026
• First Posted: July 2, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): December 1, 2032
• Study Completion (Estimated): July 1, 2034
• Last Updated: July 15, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)